Examining medicine shortages and their consequences through economic, clinical, and economic lens
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Marstacimab Cost-Effectiveness Analysis in Hemophilia Treatment: A Portuguese Assessment
The public assessment report for Hympavzi (marstacimab) in Portugal concludes that the product offers no added therapeutic value relative to recombinant factor VIII concentrates and emicizumab in patients aged 12 years and older weighing at least 35 kg with severe hemophilia A without factor VIII...
Overcoming Challenges in Managed Entry Agreements for ATMPs
Decision-makers in England, the Netherlands, and Spain consistently identify administrative burden, outcome measurement, and data collection as the foremost obstacles to adopting managed entry agreements ATMPs. These challenges emerge most acutely when hybrid or outcome-based agreements are consi...
Workshop on AI in GMP Manufacturing: Shaping Future Guidance from EMA
The European Medicines Agency is convening a two-day multistakeholder workshop to collect expert contributions that will inform the development of Annex 22 guidance on AI in GMP Manufacturing. Date: 30 June – 1 July 2026
Format: Hybrid The event features:
...